Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

Trial Title: Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL

NCT ID: NCT06509945

Condition: Peripheral T Cell Lymphoma

Conditions: Official terms:
Lymphoma
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral

Conditions: Keywords:
peripheral T cell lymphoma
allogeneic peripheral blood stem cell transplantation
high-risk

Study type: Interventional

Study phase: N/A

Overall status: Recruiting

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Other
Intervention name: allogeneic peripheral blood stem cell transplantation
Description: Patients achieved response to treatment will receive allogeneic peripheral blood stem cell transplantation.
Arm group label: intervention arm

Summary: This study is a single-center, single-arm, prospective phase II clinical trial that evaluates the efficacy and safety of allogeneic peripheral blood stem cell transplantation in the treatment of high-risk peripheral T-cells lymphoma patients achieved complete response (CR) or partial response (PR). Conventional conditioning regimen is adopted while the reduced-intensity conditioning regimens will be preferred. Donor hematopoietic stem cell infusion is performed on day 0. All patients will undergo bone marrow examination on day 14 and day 28 post-transplant, followed by bone marrow examinations every 30 days within the first year after transplantation, and every 60 days within the second year after transplantation. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) imaging will be performed every 6 months after transplantation. If disease relapse is suspected during the follow-up period, bone marrow and relapse site examinations will be conducted at any time. The primary study endpoints are the 1-year and 2-year progression-free survival (PFS) rates post-transplant. Secondary study endpoints include the incidence of acute graft-versus-host disease (GVHD) within 180 days post-transplant, cumulative relapse rates at 1 year and 2 years post-transplant, 1-year and 2-year overall survival (OS), graft-versus-host disease-free, relapse-free survival (GRFS), non-relapse mortality (NRM), cumulative incidence of chronic GVHD, and the incidence of Cytomegalovirus （CMV）and Epstein-Barr virus（EBV）reactivation within 1 year.

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Age between 18 and less than 70 years, regardless of gender 2. Peripheral T-cell lymphoma (PTCL) was diagnosed according to the 2016 WHO criteria and met any of the following criteria: 1. High risk: IPI（International Prognostic Index） score ≥ 3 or aaIPI（age-adjusted International Prognostic Index） score ≥ 2 ( aaIPI is suitable for patients younger than 60 years old). 2. Patients who achieved complete response (CR) or partial response (PR) after first-line chemotherapy (PET-CT or CT examination was performed according to the patient 's economic conditions） 3.Patients must have a suitable hematopoietic stem cell donor: Related donors must have at least 5/10 matches for HLA-A, -B, -C, -DQB1, and - DRB1. Unrelated donors must have at least 8/10 matches for HLA-A, -B, -C, -DQB1, and -DRB1. 4.Hematopoietic cell transplantation comorbidity index (HCT-CI) score ≤ 2. 5.ECOG (Eastern Cooperative Oncology Group) performance status: 0-2. 6.Adequate liver, kidney, and cardiopulmonary function, meeting the following requirements: 1. Serum creatinine ≤ 1.5x ULN (the upper limit of normal). 2. Cardiac function: Ejection fraction ≥ 50%. 3. Baseline oxygen saturation > 92%. 4. Total bilirubin ≤ 2.0 x ULN; ALT and AST ≤ 2.0 x ULN，AKP ≤ 2.0 x ULN 5. Pulmonary function: DLCO (corrected for hemoglobin) ≥ 40% and FEV1 (Forced Expiratory Volume in 1 second) ≥ 50%. 7.Patients must have the ability to understand and be willing to participate in this study and sign an informed consent form. Exclusion Criteria: 1. PTCL patients did not meet the criteria of high-risk. 2. PTCL ALK + patients with CR after first-line treatment. 3. History of malignancies other than lymphoid tumors within the 5 years prior to screening, except for adequately treated in situ cervical cancer, basal cell carcinoma, squamous cell carcinoma of the skin, and curatively treated localized prostate cancer or ductal carcinoma in situ 4. ECOG ≥ 3. 5. HCT-CI score ≥ 3. 6. Any unstable systemic diseases, including but not limited to unstable angina, recent cerebrovascular accidents or transient ischemic attacks within the 3 months prior to screening, myocardial infarction within the 3 months prior to screening, congestive heart failure (New York Heart Association [NYHA] class ≥ III), severe arrhythmias requiring drug treatment after pacemaker implantation, significant liver, kidney, or metabolic diseases, and pulmonary arterial hypertension. 7. Active, uncontrolled infections, including those associated with hemodynamic instability, new or worsening infection symptoms or signs, new infectious lesions on imaging, or persistent unexplained fever without signs or symptoms of infection. 8. HIV-infected individuals. 9. Active hepatitis B (HBV) or active hepatitis C (HCV) requiring antiviral therapy. 10. History of autoimmune diseases 11. Pregnant or breastfeeding women. 12. Fertile males and females unwilling to use contraception during the treatment period and for 12 months after treatment.

Gender: All

Minimum age: 18 Years

Maximum age: 70 Years

Healthy volunteers: No

Locations:

Facility:
Name: Shanghai General Hospital

Address:
City: Shanghai
Zip: 200080
Country: China

Status: Recruiting

Contact:
Last name: xianmin Song, MD

Phone: 86-21-63240090

Phone ext: 3172
Email: shongxm@sjtu.edu.cn

Start date: July 15, 2024

Completion date: July 15, 2026

Lead sponsor:
Agency: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Agency class: Other

Source: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06509945